


Tolazoline

Chemical Properties

| | |
|-------------------|---|
| CAS No. : | 59-98-3 |
| Formula: | C10H12N2 |
| Molecular Weight: | 160.22 |
| Storage: | Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA. |



Biological Description

| | |
|---------------|---|
| Description | Tolazoline (Benzalolin), a non-selective competitive α -adrenergic receptor antagonist, is used as a vasodilator to treat spasms of peripheral blood vessels. It has also been used successfully as an antidote to reverse the severe peripheral vasoconstriction as a result of overdose with certain 5-HT _{2A} agonist drugs. |
| Targets(IC50) | Adrenergic Receptor |

Solubility Information

| | |
|---------------------|--|
| Solubility | DMSO: 55 mg/mL (343.28 mM), Sonication is recommended. H ₂ O: Insoluble, (< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (31.21 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 6.2414 mL | 31.2071 mL | 62.4142 mL |
| 5 mM | 1.2483 mL | 6.2414 mL | 12.4828 mL |
| 10 mM | 0.6241 mL | 3.1207 mL | 6.2414 mL |
| 50 mM | 0.1248 mL | 0.6241 mL | 1.2483 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Casbeer HC, Knych HK. Pharmacokinetics and pharmacodynamic effects of tolazoline following intravenous administration to horses. *Vet J.* 2013 Jun;196(3):504-9.
- Wei X, Qiu J, Lai R, et al. A human organoid drug screen identifies α 2-adrenergic receptor signaling as a therapeutic target for cartilage regeneration. *Cell Stem Cell.* 2024
- Yokota S, Hikasa Y, Shimura I, Kusunose S. Effects of imidazoline and nonimidazoline alpha-adrenergic agents, including xylazine, medetomidine, yohimbine, tolazoline, and atipamezole, on aggregation of bovine and equine platelets. *Am J Vet Res.* 2013 Mar;74(3):395-402.
- Contreras CD, Ledesma AE, Zinzuk J, Brandán SA. Vibrational study of tolazoline hydrochloride by using FTIR-Raman and DFT calculations. *Spectrochim Acta A Mol Biomol Spectrosc.* 2011 Sep;79(5):1710-4.
- Mortenson JA, Robison JA. Tolazoline-induced apnea in mule deer (*Odocoileus hemionus*). *J Zoo Wildl Med.* 2011 Mar;42(1):105-7.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481